Effect of empagliflozin on endothelial function in patients with type 2 diabetes and cardiovascular disease: Results from the multicenter, randomized, placebo- controlled, double-blind EMBLEM trial

Atsushi Tanaka, Michio Shimabukuro, Noritaka MacHii, Hiroki Teragawa, Yosuke Okada, Kosuke R. Shima, Toshinari Takamura, Isao Taguchi, Itaru Hisauchi, Shigeru Toyoda, Yasushi Matsuzawa, Hirofumi Tomiyama, Minako Yamaoka-Tojo, Hisako Yoshida, Yasunori Sato, Yumi Ikehara, Shinichiro Ueda, Yukihito Higashi, Koichi Node

Research output: Contribution to journalLetter

1 Citation (Scopus)
Original languageEnglish
Pages (from-to)E159-E161
JournalDiabetes care
Volume42
Issue number10
DOIs
Publication statusPublished - 2019 Oct 1

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialised Nursing

Cite this

Tanaka, A., Shimabukuro, M., MacHii, N., Teragawa, H., Okada, Y., Shima, K. R., Takamura, T., Taguchi, I., Hisauchi, I., Toyoda, S., Matsuzawa, Y., Tomiyama, H., Yamaoka-Tojo, M., Yoshida, H., Sato, Y., Ikehara, Y., Ueda, S., Higashi, Y., & Node, K. (2019). Effect of empagliflozin on endothelial function in patients with type 2 diabetes and cardiovascular disease: Results from the multicenter, randomized, placebo- controlled, double-blind EMBLEM trial. Diabetes care, 42(10), E159-E161. https://doi.org/10.2337/dc19-1177